专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明授权

US4235885A Inhibitors of mammalian collagenase 失效
标题翻译：哺乳动物胶原酶抑制剂
公开(公告)号：US4235885A
公开(公告)日：1980-11-25
申请号：US51915
申请日：1979-06-25
申请人： Joseph E. Sundeen , Tamara Dejneka
发明人： Joseph E. Sundeen , Tamara Dejneka
IPC分类号： A61K31/095 , A61K31/195 , A61K38/00 , A61P43/00 , C07C51/08 , C07C51/367 , C07C51/377 , C07C51/58 , C07C67/00 , C07C313/00 , C07C319/18 , C07C319/20 , C07C323/52 , C07C323/60 , C07C325/00 , C07C327/20 , C07C327/32 , C07K1/113 , C07K5/02 , C07K5/06 , C07K14/81 , A61K37/00 , A01N37/00 , A01N37/30
CPC分类号： C07C51/377 , C07C323/00 , C07C327/00 , C07C51/08 , C07C51/367 , C07C51/58 , C07K5/06026 , A61K38/00 , Y10S514/821
摘要： Mammalian collagenase is inhibited by compounds having the formula ##STR1## and salts thereof, wherein R.sub.1 is hydrogen or alkanoyl of 2 to 10 carbon atoms;R.sub.2 is hydroxy, amino, or ##STR2## R.sub.3 is hydrogen, alkyl of 1 to 4 carbon atoms, ##STR3## R.sub.4 is hydroxy, amino, arginine, leucine, glutamine, alanine or glycine; andm is 0 or an integer of 1 to 9.
摘要翻译：哺乳动物胶原酶被具有式“IMAGE”的化合物及其盐抑制，其中R1是氢或2-10个碳原子的烷酰基; R2是羟基，氨基或R3是氢，1-4个碳原子的烷基，R4是羟基，氨基，精氨酸，亮氨酸，谷氨酰胺，丙氨酸或甘氨酸; m为0或1〜9的整数。

2. 发明授权

US4122083A 1,2,3,4-Tetrahydropyrido[4',3':4.5]thiazolo-[3,2-a]benzimidazoles 失效
标题翻译： 1,2,3,4-四氢吡啶{8-4 {40,3 {40：4.5 {9噻唑并[8,2-a {9苯并咪唑
公开(公告)号：US4122083A
公开(公告)日：1978-10-24
申请号：US869737
申请日：1978-01-16
申请人： Joseph E. Sundeen , Tamara Dejneka
发明人： Joseph E. Sundeen , Tamara Dejneka
IPC分类号： A61K31/435 , A61P29/00 , C07D211/74 , C07D513/14
CPC分类号： C07D513/14 , C07D211/74
摘要： The new compounds 1,2,3,4-tetrahydropyrido[4',3':4,5]-thiazolo[3,2-a]benzimidazole and derivatives thereof which have the general formula ##STR1## are useful as anti-inflammatory agents.
摘要翻译：具有通式“IMAGE”的新化合物1,2,3,4-四氢吡啶并[4'，3'：4,5] - 噻唑并[3,2-a]苯并咪唑及其衍生物可用作抗炎代理商

3. 发明授权

US08263659B2 Thyroid receptor ligands 失效
标题翻译：甲状腺受体配体
公开(公告)号：US08263659B2
公开(公告)日：2012-09-11
申请号：US12469791
申请日：2009-05-21
申请人： Denis E. Ryono , Jon J. Hangeland , Todd J. Friends , Tamara Dejneka , Pratik Devasthale , Yolanda V. Caringal , Minsheng Zhang , Arthur M. P. Doweyko , Johan Malm , Andrei Sanin
发明人： Denis E. Ryono , Jon J. Hangeland , Todd J. Friends , Tamara Dejneka , Pratik Devasthale , Yolanda V. Caringal , Minsheng Zhang , Arthur M. P. Doweyko , Johan Malm , Andrei Sanin
IPC分类号： A61K31/19 , A61K31/165 , C07C321/00 , C07C229/00 , C07C59/00
CPC分类号： C07C311/46 , A61K31/4439 , A61K31/662 , A61K45/06 , C07C43/29 , C07C43/295 , C07C59/68 , C07C59/72 , C07C65/24 , C07C65/26 , C07C69/16 , C07C69/736 , C07C69/94 , C07C205/38 , C07C217/58 , C07C233/29 , C07C235/34 , C07C235/42 , C07C235/46 , C07C235/52 , C07C235/60 , C07C235/62 , C07C235/64 , C07C311/37 , C07C2601/02 , C07C2601/14 , C07C2602/08 , C07C2603/18 , C07D213/30 , C07D239/26 , C07D257/04 , C07D263/14 , C07D263/32 , C07D277/24 , C07D285/06 , C07D307/42 , C07D307/52 , C07D307/87 , C07D317/58 , C07D317/60 , C07D333/32 , C07F9/306 , C07F9/3241 , C07F9/4056 , A61K2300/00
摘要： A method is provided for preventing, inhibiting or treating diseases or disorders associated with metabolism dysfunction or which are dependent upon the expression of a T3 regulated gene, wherein a compound as described in the general formula I below is administered in a therapeutically effective amount:
摘要翻译：提供了一种用于预防，抑制或治疗与代谢功能障碍相关或与T3调节基因的表达有关的疾病或病症的方法，其中以治疗有效量施用下述通式I中所述的化合物：

4. 发明授权

US4382081A Inhibitors of mammalian collagenase 失效
标题翻译：哺乳动物胶原酶抑制剂
公开(公告)号：US4382081A
公开(公告)日：1983-05-03
申请号：US273142
申请日：1981-06-12
申请人： Joseph E. Sundeen , Tamara Dejneka
发明人： Joseph E. Sundeen , Tamara Dejneka
IPC分类号： C12N9/99 , A61K31/195 , A61K38/00 , A61K38/55 , C07C55/02 , C07C67/00 , C07C313/00 , C07C323/52 , C07C323/56 , C07C323/60 , C07C327/20 , C07C327/32 , C07K5/02 , C07K5/04 , C07K5/06 , C07K5/08 , C07K5/083 , C07K5/10 , C07K5/103 , C07K14/81 , A61K37/00 , C07C103/52
CPC分类号： C07K5/1008 , C07C323/52 , C07C323/56 , C07C327/00 , C07C55/02 , C07K5/06026 , C07K5/0806
摘要： Mammalian collagenase is inhibited by compounds of the formula ##STR1## or salts thereof, wherein R is hydrogen, alkanoyl of 2 to 10 carbon atoms or arylcarbonyl;R.sub.1 is of 3 to 8 carbon atoms, cycloalkyl of 3 to 7 carbon atoms, aryl or arylalkyl; ##STR2## R.sub.4 is hydrogen, methyl, ethyl, or ##STR3## R.sub.5 and R.sub.6 are each independently selected as --OCH.sub.3 or --OCH.sub.2 CH.sub.3 or are combined as --OCH.sub.2 CH.sub.2 O-- or --O--(CH.sub.2)--O--;R.sub.7 and R.sub.8 are each independently selected as hydrogen, methyl or ethyl or are combined as --(CH.sub.2).sub.4 --, --(CH.sub.2).sub.5 -- or --CH.sub.2 CH.sub.2 --O--CH.sub.2 CH.sub.2 --;R.sub.9 is hydrogen, methyl, ethyl ##STR4## m is an integer from 0 to 7; p is an integer from 1 to 3; AA.sub.n is an amino acid chain of from one to three amino acids; n is 1 or 1, 2 or 1, 2, 3;when p is 1, AA.sub.n is AA.sub.1 ;when p is 2, AA.sub.n is AA.sub.1 --AA.sub.2 ;when p is 3, AA.sub.n is AA.sub.1 --AA.sub.2 --AA.sub.3 ;AA.sub.1 is glycine or alanine;AA.sub.2 is glycine or alanine;AA.sub.3 is leucine, glutamine or isoleucine.A method of reducing the adverse effects of mammalian collagenase in a mammalian host in need thereof, which comprises administering to the mammal an effective amount of a compound having the above formula is within the scope of the invention.
摘要翻译：哺乳动物胶原酶被下式化合物或其盐抑制，其中R是氢，2-10个碳原子的烷酰基或芳基羰基; R1为3〜8个碳原子的烷基，3〜7个碳原子的环烷基，芳基或芳基烷基; R 4是氢，甲基，乙基或者R 5，R 6和R 6各自独立地选自-OCH 3或-OCH 2 CH 3，或者作为-OCH 2 CH 2 O-或-O - （CH 2）-O-; R 7和R 8各自独立地选自氢，甲基或乙基，或者作为 - （CH 2）4 - ， - （CH 2）5 - 或-CH 2 CH 2 -O-CH 2 CH 2 - R9是氢，甲基，乙基，是0至7的整数; p是1至3的整数; AAn是一至三个氨基酸的氨基酸链; n为1或1,2或1，2，3; 当p为1时，AAn为AA1; 当p为2时，AAn为AA1-AA2; 当p为3时，AAn为AA1-AA2-AA3; AA1是甘氨酸或丙氨酸; AA2是甘氨酸或丙氨酸; AA3是亮氨酸，谷氨酰胺或异亮氨酸。减少有需要的哺乳动物宿主中哺乳动物胶原酶的不利影响的方法，其包括向哺乳动物施用有效量的具有上式的化合物在本发明的范围内。

5. 发明授权

US4812564A Process for preparing 4,4-dialkyl-2-azetidinones utilizing a pyridine (or substituted pyridine) sulfur trioxide complex 失效
标题翻译：使用吡啶（或取代的吡啶）三氧化硫络合物制备4,4-二烷基-2-氮杂环丁酮的方法
公开(公告)号：US4812564A
公开(公告)日：1989-03-14
申请号：US48439
申请日：1987-05-11
申请人： William A. Slusarchyk , Tamara Dejneka
发明人： William A. Slusarchyk , Tamara Dejneka
IPC分类号： C07D205/085 , C07D213/18 , C07D417/12 , C07D205/08
CPC分类号： C07D417/12 , C07D205/085 , C07D213/18
摘要： Disclosed herein is a process for preparing a compound having the formula ##STR1## which comprises sulfonating a compound having the formula ##STR2## with a complex having the formula ##STR3## and cyclizing the resulting compound having the formula ##STR4## by treatment with a base.
摘要翻译：本文公开了一种制备具有式“IMAGE”的化合物的方法，其包括用具有式“IMAGE”的络合物磺化具有式“IMAGE”的化合物，并使所得到的具有式“IMAGE”的化合物通过用基础。

6. 发明授权

US4686298A Intermediates for alpha-acyloxy phosphonate angiotensin converting enzyme inhibitors 失效
标题翻译： α-酰氧基膦酸盐血管紧张素转换酶抑制剂的中间体
公开(公告)号：US4686298A
公开(公告)日：1987-08-11
申请号：US10880
申请日：1987-02-04
申请人： Donald S. Karanewsky , Tamara Dejneka
发明人： Donald S. Karanewsky , Tamara Dejneka
IPC分类号： C07F9/40 , C07F9/42 , C07F9/568 , C07F9/572 , C07F9/59 , C07F9/6571 , C07F9/58 , C07F9/65
CPC分类号： C07F9/657181 , C07F9/4075 , C07F9/425 , C07F9/5683 , C07F9/572 , C07F9/591
摘要： Compounds of the formula ##STR1## are useful in the preparation of .alpha.-acyloxy phosphonate compounds. The final products are useful as anti-hypertensive agents due to their angiotensin converting enzyme inhibition activity.
摘要翻译：式“IMAGE”的化合物可用于制备α-酰氧基膦酸酯化合物。由于其血管紧张素转换酶抑制活性，最终产品可用作抗高血压药。

7. 发明授权

US4670422A .alpha.-acyloxy phosphonate angiotensin converting enzyme inhibitors 失效
标题翻译： α-酰基膦酸盐血管紧张素转换酶抑制剂
公开(公告)号：US4670422A
公开(公告)日：1987-06-02
申请号：US844635
申请日：1986-03-27
申请人： Donald S. Karanewsky , Tamara Dejneka
发明人： Donald S. Karanewsky , Tamara Dejneka
IPC分类号： C07F9/38 , A61K31/66 , A61K31/665 , A61K31/67 , A61K31/675 , A61P9/12 , A61P25/04 , C07F9/40 , C07F9/568 , C07F9/572 , C07F9/58 , C07F9/59 , C07F9/62 , C07F9/6503 , C07F9/6506 , C07F9/6509 , C07F9/653 , C07F9/6539 , C07F9/655 , C07F9/6553 , C07F9/6558 , C07F9/6561 , C07F9/6571 , C07F9/32 , C07F9/65
CPC分类号： C07F9/591 , C07F9/5683 , C07F9/572 , C07F9/657181
摘要： Compounds of the formula ##STR1## wherein X is various amino or imino acids and esters are disclosed. These compounds are useful as anti-hypertensive agents due to their angiotensin converting enzyme inhibition activity and depending upon the definition of X may also be useful as analgesics due to their enkephalinase inhibition activity.
摘要翻译：公开了其中X是各种氨基或亚氨基酸和酯的式“IMAGE”的化合物。这些化合物由于其血管紧张素转化酶抑制活性而可用作抗高血压剂，并且根据X的定义，由于其脑啡肽酶抑制活性也可用作镇痛药。

8. 发明授权

US4288456A Compositions containing 1-aryl-5-(2-propenylamino)-1-penten-3-ones and method for treating inflammatory conditions 失效
标题翻译：含有1-芳基-5-（2-丙烯基氨基）-1-戊烯-3-酮的组合物和治疗炎性病症的方法
公开(公告)号：US4288456A
公开(公告)日：1981-09-08
申请号：US188647
申请日：1980-09-19
申请人： Joseph E. Sundeen , Tamara Dejneka , Frederic P. Hauck
发明人： Joseph E. Sundeen , Tamara Dejneka , Frederic P. Hauck
IPC分类号： C07C229/38 , A61K31/135
CPC分类号： C07C229/38 , Y10S514/825
摘要： Pharmaceutical compositions containing 1-aryl-5-(2-propenylamino)-1-penten-3-ones and salts thereof having the structure ##STR1## wherein R.sup.1 is hydrogen, lower alkyl, lower alkoxy, halogen, hydroxy, lower alkanoyloxy, nitro, cyano, amino, carboxy or lower alkoxycarbonyl, and R.sup.2, R.sup.3, R.sup.4 and R.sup.5 are the same or different and are hydrogen or lower alkyl. These compositions are useful in treating inflammatory conditions.
摘要翻译：含有1-芳基-5-（2-丙烯基氨基）-1-戊烯-3-酮及其盐的药物组合物，其结构为：其中R1为氢，低级烷基，低级烷氧基，卤素，羟基，低级烷酰氧基，硝基，氰基，氨基，羧基或低级烷氧基羰基，R 2，R 3，R 4和R 5相同或不同，为氢或低级烷基。这些组合物可用于治疗炎性病症。

9. 发明授权

US07557143B2 Thyroid receptor ligands 失效
标题翻译：甲状腺受体配体
公开(公告)号：US07557143B2
公开(公告)日：2009-07-07
申请号：US10826100
申请日：2004-04-15
申请人： Denis E. Ryono , Jon J. Hangeland , Todd J. Friends , Tamara Dejneka , Pratik Devasthale , Yolanda V. Caringal , Minsheng Zhang , Arthur M. P. Doweyko , Johan Malm , Andrei Sanin
发明人： Denis E. Ryono , Jon J. Hangeland , Todd J. Friends , Tamara Dejneka , Pratik Devasthale , Yolanda V. Caringal , Minsheng Zhang , Arthur M. P. Doweyko , Johan Malm , Andrei Sanin
IPC分类号： A61K31/165 , A61K31/19 , C07C239/00 , C07C325/00 , C07C229/00 , C07C59/00
CPC分类号： C07C311/46 , A61K31/4439 , A61K31/662 , A61K45/06 , C07C43/29 , C07C43/295 , C07C59/68 , C07C59/72 , C07C65/24 , C07C65/26 , C07C69/16 , C07C69/736 , C07C69/94 , C07C205/38 , C07C217/58 , C07C233/29 , C07C235/34 , C07C235/42 , C07C235/46 , C07C235/52 , C07C235/60 , C07C235/62 , C07C235/64 , C07C311/37 , C07C2601/02 , C07C2601/14 , C07C2602/08 , C07C2603/18 , C07D213/30 , C07D239/26 , C07D257/04 , C07D263/14 , C07D263/32 , C07D277/24 , C07D285/06 , C07D307/42 , C07D307/52 , C07D307/87 , C07D317/58 , C07D317/60 , C07D333/32 , C07F9/306 , C07F9/3241 , C07F9/4056 , A61K2300/00
摘要： Thyroid receptor ligands are provided which have the general formula I wherein: R1 is R2 and R3 are the same or different and are hydrogen, halogen, alkyl of 1 to 4 carbons or cycloalkyl of 3 to 5 carbons, provided that at least one of R2 and R3 is other than hydrogen; R4 is R5 and R6 are the same or different and are selected from hydrogen, aryl, heteroaryl, alkyl, cycloalkyl, aralkyl or heteroaralkyl. R7 is aryl, heteroaryl, alkyl, aralkyl, or heteroaralkyl; R8 is aryl, heteroaryl, or cycloalkyl; R9 is R7 or hydrogen; R10 is hydrogen, halogen, cyano or alkyl; R11 and R12 are each independently selected from the group consisting of hydrogen, halogen, alkoxy, hydroxy (—OH) cyano, and alkyl; R13 is carboxylic acid (COOH) or esters thereof, phosphonic and phosphinic acid or esters thereof, sulfonic acid, tetrazole, hydroxamic acid, thiazolidinedione, acylsulfonamide, or other carboxylic acid surrogates known in the art; R14 and R15 may be the same or different and are selected from hydrogen and alkyl, or R14 and R15 may be joined together forming a chain of 2 to 5 methylene groups [—(CH2)m-, m=2, 3, 4 or 5], thus forming 3- to 6-membered cycloalkyl rings; R16 is hydrogen or alkyl of 1 to 4 carbons; R17 and R18 are the same or different and selected from hydrogen, halogen and alkyl; n is 0 or an integer from 1 to 4; X is oxygen (—O—), sulfur (—S—), sulfonyl (—SO2—), sulfenyl (—SO—) selenium (—Se—), carbonyl (—CO—), amino (—NH—) or methylene (—CH2-); wherein the substituents are as described herein. In addition, a method is provided for preventing, inhibiting or treating diseases or disorders associated with metabolism dysfunction or which are dependent upon the expression of a T3 regulated gene, wherein a compound as described above is administered in a therapeutically effective amount.
摘要翻译：提供具有通式I的甲状腺受体配体，其中：R 1是R 2和R 3相同或不同，是氢，卤素，1至4个碳的烷基或3至5个碳原子的环烷基，条件是R2中的至少一个并且R 3不是氢; R 4是R 5和R 6相同或不同，并且选自氢，芳基，杂芳基，烷基，环烷基，芳烷基或杂芳烷基。 R7是芳基，杂芳基，烷基，芳烷基或杂芳烷基; R8是芳基，杂芳基或环烷基; R9为R7或氢; R 10是氢，卤素，氰基或烷基; R 11和R 12各自独立地选自氢，卤素，烷氧基，羟基（-OH）氰基和烷基; R13是羧酸（COOH）或其酯，膦酸和次膦酸或其酯，磺酸，四唑，异羟肟酸，噻唑烷二酮，酰基磺酰胺或本领域已知的其它羧酸替代物; R 14和R 15可以相同或不同，并且选自氢和烷基，或者R 14和R 15可以连接在一起形成2至5个亚甲基 - [ - （CH 2）m - ，m = 2,3,4或 5]，从而形成3-至6-元环烷基环; R16是氢或1至4个碳的烷基; R 17和R 18相同或不同，选自氢，卤素和烷基; n为0或1至4的整数; X是氧（-O-），硫（-S-），磺酰基（-SO 2 - ），亚磺酰基（-SO-），硒（-Se-），羰基（-CO-），氨基（-NH-）或亚甲基（-CH2-）; 其中取代基如本文所述。此外，提供了一种用于预防，抑制或治疗与代谢功能障碍相关或依赖于T3调节基因的表达的疾病或病症的方法，其中如上所述的化合物以治疗有效量施用。

10. 发明申请

US20050004184A1 Thyroid receptor ligands 失效
标题翻译：甲状腺受体配体
公开(公告)号：US20050004184A1
公开(公告)日：2005-01-06
申请号：US10826100
申请日：2004-04-15
申请人： Denis Ryono , Jon Hangeland , Todd Friends , Tamara Dejneka , Pratik Devasthale , Yolanda Caringal , Minsheng Zhang , Arthur Doweyko , Johan Malm , Andrei Sanin
发明人： Denis Ryono , Jon Hangeland , Todd Friends , Tamara Dejneka , Pratik Devasthale , Yolanda Caringal , Minsheng Zhang , Arthur Doweyko , Johan Malm , Andrei Sanin
IPC分类号： A61K20060101 , A61K31/16 , A61K31/165 , A61K31/19 , A61K31/277 , A61K31/421 , A61K31/44 , A61K47/00 , C07C205/00 , C07C235/20 , C07C255/49 , C07C381/00
CPC分类号： C07C311/46 , A61K31/4439 , A61K31/662 , A61K45/06 , C07C43/29 , C07C43/295 , C07C59/68 , C07C59/72 , C07C65/24 , C07C65/26 , C07C69/16 , C07C69/736 , C07C69/94 , C07C205/38 , C07C217/58 , C07C233/29 , C07C235/34 , C07C235/42 , C07C235/46 , C07C235/52 , C07C235/60 , C07C235/62 , C07C235/64 , C07C311/37 , C07C2601/02 , C07C2601/14 , C07C2602/08 , C07C2603/18 , C07D213/30 , C07D239/26 , C07D257/04 , C07D263/14 , C07D263/32 , C07D277/24 , C07D285/06 , C07D307/42 , C07D307/52 , C07D307/87 , C07D317/58 , C07D317/60 , C07D333/32 , C07F9/306 , C07F9/3241 , C07F9/4056 , A61K2300/00
摘要： Thyroid receptor ligands are provided which have the general formula I wherein: R1 is R2 and R3 are the same or different and are hydrogen, halogen, alkyl of 1 to 4 carbons or cycloalkyl of 3 to 5 carbons, provided that at least one of R2 and R3 is other than hydrogen; R4 is R5 and R6 are the same or different and are selected from hydrogen, aryl, heteroaryl, alkyl, cycloalkyl, aralkyl or heteroaralkyl. R7 is aryl, heteroaryl, alkyl, aralkyl, or heteroaralkyl; R8 is aryl, heteroaryl, or cycloalkyl; R9 is R7 or hydrogen; R10 is hydrogen, halogen, cyano or alkyl; R11 and R12 are each independently selected from the group consisting of hydrogen, halogen, alkoxy, hydroxy (—OH) cyano, and alkyl; R13 is carboxylic acid (COOH) or esters thereof, phosphonic and phosphinic acid or esters thereof, sulfonic acid, tetrazole, hydroxamic acid, thiazolidinedione, acylsulfonamide, or other carboxylic acid surrogates known in the art; R14 and R15 may be the same or different and are selected from hydrogen and alkyl, or R14 and R15 may be joined together forming a chain of 2 to 5 methylene groups [—(CH2)m-, m=2, 3, 4 or 5], thus forming 3- to 6-membered cycloalkyl rings; R16 is hydrogen or alkyl of 1 to 4 carbons; R17 and R18 are the same or different and selected from hydrogen, halogen and alkyl; n is 0 or an integer from 1 to 4; X is oxygen (—O—), sulfur (—S—), sulfonyl (—SO2—), sulfenyl (—SO—) selenium (—Se—), carbonyl (—CO—), amino (—NH—) or methylene (—CH2-); wherein the substituents are as described herein. In addition, a method is provided for preventing, inhibiting or treating diseases or disorders associated with metabolism dysfunction or which are dependent upon the expression of a T3 regulated gene, wherein a compound as described above is administered in a therapeutically effective amount.
摘要翻译：提供具有通式I的甲状腺受体配体，其中：R 1是R 2和R 3相同或不同，是氢，卤素，1至4个碳的烷基或3至5个碳原子的环烷基，条件是R2中的至少一个并且R 3不是氢; R 4是R 5和R 6相同或不同，并且选自氢，芳基，杂芳基，烷基，环烷基，芳烷基或杂芳烷基。 R7是芳基，杂芳基，烷基，芳烷基或杂芳烷基; R8是芳基，杂芳基或环烷基; R9为R7或氢; R 10是氢，卤素，氰基或烷基; R 11和R 12各自独立地选自氢，卤素，烷氧基，羟基（-OH）氰基和烷基; R13是羧酸（COOH）或其酯，膦酸和次膦酸或其酯，磺酸，四唑，异羟肟酸，噻唑烷二酮，酰基磺酰胺或本领域已知的其它羧酸替代物; R 14和R 15可以相同或不同，并且选自氢和烷基，或者R 14和R 15可以连接在一起形成2至5个亚甲基 - [ - （CH 2）m - ，m = 2,3,4或 5]，从而形成3-至6-元环烷基环; R16是氢或1至4个碳的烷基; R 17和R 18相同或不同，选自氢，卤素和烷基; n为0或1至4的整数; X是氧（-O-），硫（-S-），磺酰基（-SO 2 - ），亚磺酰基（-SO-）硒（-Se-），羰基（-CO-），氨基（-NH-）或亚甲基（-CH 2 - ）其中取代基如本文所述。此外，提供了一种用于预防，抑制或治疗与代谢功能障碍相关或依赖于T3调节基因的表达的疾病或病症的方法，其中如上所述的化合物以治疗有效量施用。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式